<DOC>
	<DOC>NCT02860052</DOC>
	<brief_summary>This is a phase 2, multi-center, double-blind, randomized, vehicle-controlled study to be conducted in approximately 170 non immunocompromised adult subjects with interdigital tinea pedis. Subjects will apply the investigational product (IP) (SB208 or Vehicle Gel) to the interdigital areas and all affected and immediate surrounding areas of one or both feet once daily for 2 weeks, followed by a 4-week post-treatment observation period.</brief_summary>
	<brief_title>SB208 for the Treatment of Tinea Pedis</brief_title>
	<detailed_description />
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Tinea Pedis</mesh_term>
	<criteria>Otherwise healthy male and female subjects with clinical diagnosis of interdigital t. pedis T.pedis provisionally confirmed at baseline by a positive KOH wet mount for segmented fungal hyphae on skin scraping from the target site Women who are pregnant or nursing or planning on becoming pregnant Subjects with onychomycosis or moccasintype t. pedis Subjects using topical or systemic antifungal agents</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>